Rinvoq nabs new approval in second-line UC; Sensorion says its failed drug now works in subset analysis
AbbVie’s Rinvoq racked up another approval late Wednesday afternoon.
The drug is now OK’d in adults with moderately to severely active ulcerative colitis who have …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
